Welcome to our dedicated page for Helius Med Technologies news (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Helius Med Technologies stock.
Helius Medical Technologies Inc (NASDAQ: HSDT) is a pioneering neurotechnology company focused on non-invasive therapies for neurological deficits. This page provides investors and healthcare professionals with essential updates on HSDT's progress, including regulatory milestones, clinical trial results, and strategic initiatives.
Discover the latest developments surrounding the Portable Neuromodulation Stimulator (PoNS), partnerships with medical institutions, and financial performance updates. Our curated news collection ensures you stay informed about HSDT's advancements in neuroplasticity-based treatments for conditions like multiple sclerosis and traumatic brain injury.
This resource aggregates official press releases, earnings reports, and market-related announcements. Key coverage areas: FDA regulatory updates, clinical study outcomes, executive leadership changes, and technology licensing agreements. Bookmark this page for streamlined access to material information impacting HSDT's position in the medical device sector.
Helius Medical Technologies (Nasdaq: HSDT), a neurotech company specializing in therapeutic neuromodulation for balance and gait deficits, has achieved full compliance with Nasdaq's continued listing requirements. The company received formal confirmation on July 7, 2025 from the Nasdaq Hearings Panel regarding compliance with the equity requirement (Rule 5550(b)(1)).
This follows their earlier compliance confirmation with the minimum bid price requirement (Rule 5550(a)(2)) received on June 3, 2025. The company will be subject to a Mandatory Panel Monitor for one year following this notification.
Helius Medical Technologies (Nasdaq:HSDT) has announced a 1-for-50 reverse stock split of its Class A common stock, effective June 30, 2025. The split will reduce outstanding shares from approximately 33.8 million to 0.7 million, while maintaining the authorized share count at 150 million.
Trading on the split-adjusted basis will begin July 1, 2025, under the same symbol "HSDT" but with a new CUSIP number (42328V 876). The reverse split was approved by stockholders on May 23, 2025, authorizing a ratio range of 1-for-2 to 1-for-250, with the final 1-for-50 ratio determined by the Board of Directors.
Helius Medical Technologies (NASDAQ: HSDT) has secured reimbursement approval from United Healthcare for its Portable Neuromodulation Stimulator (PoNS®) Device, making it the second major healthcare provider after Anthem to offer coverage. The approved reimbursement amount totals $18,100, which includes patient co-payment and represents the adjusted list price for out-of-network status.
The PoNS Device is designed to improve balance and gait deficits while reducing fall risk. This development marks a significant milestone in Helius's strategy to expand patient access through commercial payor coverage and third-party reimbursement, particularly benefiting MS patients.
Helius Medical Technologies has announced a 1-for-15 reverse stock split of its Class A common stock, effective May 1, 2025. The split was approved by stockholders on April 21, 2025, allowing a ratio range of 1-for-2 to 1-for-30 to maintain Nasdaq listing compliance.
Starting May 2, 2025, the company's stock will trade on a split-adjusted basis under the same symbol "HSDT" on the Nasdaq Capital Market. The reverse split will reduce outstanding shares from approximately 7.9 million to 0.5 million, while maintaining the authorized share count at 150 million.
Key changes include:
- Every 15 shares will convert to one share
- $0.001 par value remains unchanged
- Fractional shares will be rounded down with cash compensation
- New CUSIP number: 42328V 884
- Proportional adjustments to stock options and warrants